Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $17.93.

Several research firms have weighed in on ROIV. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, November 13th. Bank of America boosted their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research report on Wednesday, September 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th.

Insider Buying and Selling at Roivant Sciences

In related news, COO Eric Venker sold 177,704 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16. Following the completion of the sale, the chief operating officer now owns 740,976 shares of the company’s stock, valued at $8,550,863.04. This represents a 19.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CIO Mayukh Sukhatme sold 412,584 shares of the stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $12.05, for a total transaction of $4,971,637.20. Following the completion of the transaction, the executive now owns 18,836,547 shares of the company’s stock, valued at $226,980,391.35. This represents a 2.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,942,629 shares of company stock valued at $23,071,486 in the last ninety days. Company insiders own 7.90% of the company’s stock.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently made changes to their positions in ROIV. Mutual of America Capital Management LLC raised its holdings in Roivant Sciences by 0.4% during the second quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock worth $3,457,000 after purchasing an additional 1,142 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Roivant Sciences by 23.2% during the 2nd quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock valued at $89,000 after purchasing an additional 1,603 shares during the period. Covestor Ltd raised its stake in shares of Roivant Sciences by 9.1% in the 3rd quarter. Covestor Ltd now owns 19,190 shares of the company’s stock worth $222,000 after buying an additional 1,605 shares in the last quarter. US Bancorp DE raised its stake in shares of Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares in the last quarter. Finally, Quarry LP lifted its holdings in shares of Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after buying an additional 2,500 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Trading Up 2.1 %

Shares of NASDAQ ROIV opened at $12.08 on Friday. The business has a 50 day simple moving average of $11.92 and a 200-day simple moving average of $11.56. Roivant Sciences has a twelve month low of $9.69 and a twelve month high of $13.06. The company has a market capitalization of $8.79 billion, a price-to-earnings ratio of 2.14 and a beta of 1.25.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.